Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,632.19
(
-0.61%
)
US TECH 100
23,737.60
(
-0.64%
)
Dow Jones
46,558.47
(
-0.26%
)
Brent Oil
101.58
(
0.00%
)
Bitcoin
71,738.55
(
0.73%
)
News Focus
News Focus
Post# of 257242
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122787
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 246409

Tuesday, 06/06/2023 12:17:12 PM

Tuesday, June 06, 2023 12:17:12 PM

Post# of 257242
MRNA/MRK may seek accelerated approval for melanoma cancer vaccine based on phase-2 data; a phase-3 trial is expected to start in 3Q23 (which could serve as the "confirmatory" trial for an AA):

https://finance.yahoo.com/news/1-cancer-vaccines-poised-unlock-011448754.html

It is by no means clear that the phase-2 dataset is sufficient for an FDA accelerated approval, but MRNA likes to talk a big game.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now